MedPath

Incepta Pharmaceuticals Ltd.

Incepta Pharmaceuticals Ltd. logo
🇧🇩Bangladesh
Ownership
Private
Established
1999-01-01
Employees
5K
Market Cap
-
Website
http://www.inceptapharma.com

Clinical Trials

7

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:4

Drug Approvals

1

PHILIPPINES:1

Drug Approvals

Adnerv

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (66.7%)
Phase 1
1 (16.7%)
Phase 2
1 (16.7%)

PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).

Phase 3
Recruiting
Conditions
Healthy
Interventions
First Posted Date
2025-06-17
Last Posted Date
2025-06-17
Lead Sponsor
Incepta Pharmaceuticals Ltd
Target Recruit Count
56
Registration Number
NCT07025681
Locations
🇧🇩

Universal Medical College and Hospital, Dhaka, Bangladesh

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

Phase 1
Completed
Conditions
Breast Cancer
Breast Neoplasms
Breast Disease
Antineoplastic Agents
Interventions
Drug: Trastuzumab (proposed Trastuzumab biosimilar)
Drug: Herclon
First Posted Date
2025-03-20
Last Posted Date
2025-07-22
Lead Sponsor
Incepta Pharmaceuticals Ltd
Target Recruit Count
80
Registration Number
NCT06886659
Locations
🇧🇩

Al-Manar Hospital Ltd,, Dhaka, Bangladesh

🇧🇩

Universal Medical College, Dhaka, Bangladesh

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Phase 3
Recruiting
Conditions
Diabetic Macular Edema
Retinal Disease
Macular Edema
Diabetic Retinopathy
Macular Degeneration
Retinal Degeneration
Interventions
First Posted Date
2024-03-12
Last Posted Date
2025-06-06
Lead Sponsor
Incepta Pharmaceuticals Ltd
Target Recruit Count
70
Registration Number
NCT06305416
Locations
🇧🇩

Bangladesh Eye Hospital & Institute, Dhaka, Bangladesh

Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

Phase 3
Conditions
Covid19
Interventions
Drug: Placebo
First Posted Date
2021-09-24
Last Posted Date
2021-09-28
Lead Sponsor
Incepta Pharmaceuticals Ltd
Target Recruit Count
480
Registration Number
NCT05056558
Locations
🇧🇩

Dhaka Medical College, Mugda Medical College, Kuwait Bangladesh Friendship Government Hospital, Dhaka, Bangladesh

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.